Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2015
At a glance
- Drugs BC 819 (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors BioCancell Therapeutics
- 01 Oct 2015 Status changed from active, no longer recruiting to completed, as per BioCancell media release.
- 23 Jul 2014 Planned End Date changed from 1 Feb 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 12 Jun 2013 Planned end date changed from 1 Dec 2012 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History